Neuroendocrine Tumor Market to Register Incremental Growth During the Forecast Period (2024-2034), Asserts DelveInsight | ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma

Posted on
by

Neuroendocrine Tumor Market to Register Incremental Growth During the Forecast Period (2024-2034), Asserts DelveInsight | ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma
The Neuroendocrine Tumor Market Forecast report offers an in-depth understanding of the Neuroendocrine Tumor, historical and forecasted epidemiology as well as the Neuroendocrine Tumor market trends in the 7MM.

The Neuroendocrine Tumor market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neuroendocrine Tumor pipeline products will significantly revolutionize the Neuroendocrine Tumor market dynamics.  

 

DelveInsight’s “Neuroendocrine Tumor Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neuroendocrine Tumor, historical and forecasted epidemiology as well as the Neuroendocrine Tumor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Neuroendocrine Tumor market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Neuroendocrine Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neuroendocrine Tumor Market Insights

 

Some of the key facts of the Neuroendocrine Tumor Market Report: 

  • The Neuroendocrine Tumors market size is estimated to grow at a significant CAGR during the forecasted period (2020-2034) 

  • In September 2023, Novartis disclosed that the Phase III NETTER-2 trial featuring LUTATHERA achieved its primary objective. The initial therapy utilizing LUTATHERA combined with long-acting octreotide exhibited a notable enhancement in progression-free survival (PFS) among individuals diagnosed with newly diagnosed somatostatin receptor (SSTR)-positive, Grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

  • In August 2023, Exelixis reported favorable outcomes from the Phase III CABINET Pivotal Trial assessing cabozantinib in advanced pancreatic and extrapancreatic neuroendocrine tumors.

  • Neuroendocrine tumors (NETs) typically originate in the gastrointestinal (GI) tract, with the most common locations being the large intestine (20%), small intestine (19%), and appendix (4%).

  • According to Das et al. (2021), within the United States, the occurrence of NETs has surged by over six times in the past four decades. This increase primarily involves localized tumors rather than metastatic ones.

  • Key Neuroendocrine Tumor Companies: ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, and others 

  • Key Neuroendocrine Tumor Therapies: 177Lu-edotreotide PRRT, CAM2029, Surufatinib, and others 

 

Neuroendocrine Tumor Overview

According to the Neuroendocrine Tumor Patient Foundation (n.d.)- “Neuroendocrine tumors (NETs) are a complex group of tumors that develop predominantly in the digestive or respiratory tracts but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes causing them to divide uncontrollably and grow into an abnormal tissue mass (tumor)”.

 

Get a Free sample for the Neuroendocrine Tumor Market Report:

https://www.delveinsight.com/report-store/neuroendocrine-tumors-market

 

Neuroendocrine Tumor Market  

The dynamics of the Neuroendocrine Tumor market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034. 

 

Neuroendocrine Tumor Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Neuroendocrine Tumor Epidemiology Segmentation:

The Neuroendocrine Tumor market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Neuroendocrine Tumor

  • Prevalent Cases of Neuroendocrine Tumor by severity

  • Gender-specific Prevalence of Neuroendocrine Tumor

  • Diagnosed Cases of Episodic and Chronic Neuroendocrine Tumor

 

Download the report to understand which factors are driving Neuroendocrine Tumor epidemiology trends @ Neuroendocrine Tumor Epidemiological Insights

 

Neuroendocrine Tumor Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neuroendocrine Tumor market or expected to get launched during the study period. The analysis covers Neuroendocrine Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Neuroendocrine Tumor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Neuroendocrine Tumor Therapies and Key Companies

  • ITM-11: ITM Isotope Technologies Munich

  • CAM2029: Camurus

  • RYZ101: RayzeBio

  • 177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenchen

  • CAM2029: Camurus AB

  • Surufatinib: Hutchison Medipharma Limited

 

To know more about Neuroendocrine Tumor treatment, visit @ Neuroendocrine Tumor Medications

 

Neuroendocrine Tumor Market Strengths

  • NETs are often diagnosed at an early stage due to the hormonal symptoms they produce, allowing for timely intervention and better outcomes. 

  • Treatment of NETs involves a multidisciplinary team of specialists, including oncologists, surgeons, and endocrinologists, which enhances the overall management of the disease.

 

Neuroendocrine Tumor Market Opportunities

  • Continued research and development in targeted therapies, such as somatostatin analogs and molecular inhibitors, provide opportunities for more effective and personalized treatment approaches. 

  • Participation in clinical trials can lead to the discovery of new treatment modalities and contribute to the improvement of patient outcomes.

 

Scope of the Neuroendocrine Tumor Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Neuroendocrine Tumor Companies: ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, and others

  • Key Neuroendocrine Tumor Therapies: 177Lu-edotreotide PRRT, CAM2029, Surufatinib, and others

  • Neuroendocrine Tumor Therapeutic Assessment: Neuroendocrine Tumor current marketed and Neuroendocrine Tumor emerging therapies

  • Neuroendocrine Tumor Market Dynamics: Neuroendocrine Tumor market drivers and Neuroendocrine Tumor market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Neuroendocrine Tumor Unmet Needs, KOL’s views, Analyst’s views, Neuroendocrine Tumor Market Access and Reimbursement 

 

Discover more about therapies set to grab major Neuroendocrine Tumor market share @ Neuroendocrine Tumor market forecast 

 

Table of Contents 

1. Neuroendocrine Tumor Market Report Introduction

2. Executive Summary for Neuroendocrine Tumor

3. SWOT analysis of Neuroendocrine Tumor

4. Neuroendocrine Tumor Patient Share (%) Overview at a Glance

5. Neuroendocrine Tumor Market Overview at a Glance

6. Neuroendocrine Tumor Disease Background and Overview

7. Neuroendocrine Tumor Epidemiology and Patient Population

8. Country-Specific Patient Population of Neuroendocrine Tumor 

9. Neuroendocrine Tumor Current Treatment and Medical Practices

10. Neuroendocrine Tumor Unmet Needs

11. Neuroendocrine Tumor Emerging Therapies

12. Neuroendocrine Tumor Market Outlook

13. Country-Wise Neuroendocrine Tumor Market Analysis (2020–2034)

14. Neuroendocrine Tumor Market Access and Reimbursement of Therapies

15. Neuroendocrine Tumor Market Drivers

16. Neuroendocrine Tumor Market Barriers

17.  Neuroendocrine Tumor Appendix

18. Neuroendocrine Tumor Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/